Description
|
Catalog #
|
CAS#
|
Target
|
Size
|
Price ( $)
|
Casein Kinase I Inhibitor,
D4476
CK1 Inhibitor,
4-(4-(2,3-Dihydrobenzo[1,4]
dioxin-6-yl)-5-pyridin-2-yl-1H
-imidazol-2-yl)benzamide
|
SMBC1066
|
301836-43-1
|
A cell-permeable triaryl
substituted imidazolo
compound that acts as a
potent, reversible and relatively
specific ATP-competitive
inhibitor of CK1 (IC50 = 0.2 µM
from S. pombe; 0.3 µM for
CK1δ) and ALK5 (IC50 = 0.5
µM).
|
1 mg
|
120
|
MMP-2/MMP-9 Inhibitor I
(2R)-2-[(4-Biphenylylsulfony
l)amino]-3-phenylpropionic
Acid
|
SMBC1067
|
193807-58-8
|
A potent inhibitor of MMP-2
(IC50 = 310 nM) and MMP-9
(IC50 = 240 nM). Orally active in
animal models of tumor growth
and metastasis.
|
5 mg
|
145
|
Purvalanol A
2-(1R-Isopropyl-2-hydroxyet
hylamino)-6-(3-chloroanilin
o)-9-isopropyl-purine
|
SMBC1069
|
212844-53-6
|
A potent, cell-permeable,
reversible, and selective
inhibitor of cyclin-dependent
kinases (Cdks; IC50 = 4 nM for
Cdc2/cyclin B; IC50 = 70 nM for
Cdk2/cyclin A; IC50 = 35 nM for
Cdk2/cyclin E; and IC50 = 75
nM for Cdk5/p35).
|
1 mg
|
60
|
Purvalanol A
2-(1R-Isopropyl-2-hydroxyet
hylamino)-6-(3-chloroanilin
o)-9-isopropyl-purine
|
SMBC1069
|
212844-53-6
|
A potent, cell-permeable,
reversible, and selective
inhibitor of cyclin-dependent
kinases (Cdks; IC50 = 4 nM for
Cdc2/cyclin B; IC50 = 70 nM for
Cdk2/cyclin A; IC50 = 35 nM for
Cdk2/cyclin E; and IC50 = 75
nM for Cdk5/p35).
|
5 mg
|
120
|
Cell Sheet Migration
Inhibitor, Locostatin
|
SMBC1071
|
133812-16-5
|
A cell-permeable
N-(crotonyl)oxazolidinone
compound that acts as a potent
inhibitor of Raf kinase inhibitor
protein (RKIP)/Raf1 kinase
interaction. Shown to block
eukaryotic cell migration (IC50
= 14 µM for inhibition of wound
closure in MDCK cell
monolayers) and decrease
formation of lamellipodial
protrusions at the wound
margin.
|
10 mg
|
115
|
PDGFR Tyrosine Kinase
Inhibitor III
4-(6,7-Dimethoxy-4-quinazo
linyl)-N-(4-phenoxyphenyl)-1
-piperazinecarboxamide
|
SMBC1072
|
205254-94-0
|
A cell-permeable piperazinyl-
quinazoline carboxamide
compound that acts as a
potent, ATP-competitive,
reversible, and selective
inhibitor of PDGF receptor
family of tyrosine kinases (IC50
= 0.05 µM for α-PDGFR; 0.08
µM for β-PDGFR; 0.05 µM for c-
Kit; 0.23 µM for Flt3).
|
1 mg
|
102
|
1400W
N-(3-Aminomethyl)benzylac
etamidine, 2HCl
|
SMBC1075
|
214358-33-5
|
A selective, cell-permeable,
irreversible, slow, tight-binding
inhibitor of inducible nitric oxide
synthase (iNOS; Kd = 7 nM).
Suitable for use in both in vitro
and in vivo systems.
|
5 mg
|
102
|
TGF-β RI Kinase Inhibitor II
ALK5 Inhibitor II,
Transforming Growth
Factor-β Type I Receptor
Kinase Inhibitor II, 2-(3-(6-
Methylpyridin-2-yl)-1H-
pyrazol-4-yl)-1,5-
naphthyridine
|
SMBC1076
|
|
A cell-permeable naphthyridinyl
pyrazolo compound that acts as
a potent, selective, reversible,
and ATP-competitive inhibitor of
TGF-β type I receptor (ALK5;
IC50 = 23 nM, 4 nM and 18 nM
for ALK5 binding, ALK5 auto-
phosphorylation and TGF-β
cellular assay in HepG2 cells,
respectively).
|
1 mg
|
102
|
NDSB-256-4T
SB256-4T, SN2564T,
3-(4-tert-Butyl-1-pyridino)-1-
propane Sulfonate
|
SMBC1077
|
|
A non-detergent sulfobetaine
(NDSB) that prevents protein
aggregation and facilitates
protein-folding, presumably by
interacting with the early folding
intermediates.
|
5 gm
|
128
|
CL 82198
|
SMBC1079
|
|
A selective inhibitor of MMP-13
(IC50 = 10 µM). Binds to the S1′
pocket of MMP-13 with its
morpholine ring adjacent to the
catalytic zinc atom.
|
5 mg
|
95
|
Tranilast
N-(3′,4′-
Dimethoxycinnamoyl)
anthranilic Acid
|
SMBC1080
|
53902-12-8
|
An anthranilic acid analog that
acts as a potent inhibitor of
VEGF- and vascular
permeability factor-induced
angiogenesis and collagen
synthesis. Inhibits VEGF- and
PMA-stimulated PKC activity in
retinal capillary endothelial
cells without affecting the VEGF
binding or VEGF receptor
phosphorylation.
|
10 mg
|
95
|
5,6-Dichloro-1-β-D-
ribofuranosylbenzimidazole
5,6-Dichlorobenzimidazole
Riboside, DRB
|
SMBC1081
|
53-85-0
|
A potent, ATP-competitive, and
specific inhibitor of casein
kinase II (IC50 = 6 µM).
Reported to inhibit
insulin-stimulated nuclear and
cytosolic p70S6 kinase in CHO
cells.
|
50 mg
|
95
|
BAPTA, Tetrasodium Salt
|
SMBC1082
|
126824-24-6
|
Ca2+ chelator exhibiting a
105-fold greater affinity for Ca2+
(Kd = 110 nM) than for Mg2+.
After BAPTA complexes with
Ca2+, the UV spectrum shifts
from 254 to 279 nm at pH >6.0.
Useful for spectrophotometric
monitoring of extracellular Ca2+
levels, especially transient
phenomena, because of its
insensitivity to pH.
|
1 gm
|
110
|
JNK Inhibitor II, Negative
Control
N¹-Methyl-1,9-pyrazoloanthr
one
|
SMBC1088
|
|
A useful negative control for
JNK Inhibitor II (SP600125, Cat.
No. 420119). Inhibits JNK2 and
JNK3 only at much higher
concentrations (IC50 = 18 µM
and 24 µM, respectively)
compared to SP600125 (IC50 =
40 nM and 90 nM, respectively).
|
1 mg
|
58
|
IKK-2 Inhibitor VI
(5-Phenyl-2-ureido)thiophe
ne-3-carboxamide
|
SMBC1090
|
354811-10-2
|
An
ureido-thiophenecarboxamide
compound that acts as a
potent, cell-permeable,
reversible, and ATP-competitive
inhibitor of IKK-2 (IC50 = 13 nM).
|
1 mg
|
120
|
Compound 56
4-[(3-Bromophenyl)amino]-
6,7-diethoxyquinazoline
|
SMBC1094
|
171745-13-4
|
A cell-permeable, reversible,
ATP-competitive, highly potent
and specific inhibitor of the
tyrosine kinase activity of the
epidermal growth factor
receptor (IC50 = 6 pM).
|
500 μg
|
140
|
(±)-Blebbistatin
|
SMBC1095
|
674289-55-5
|
A cell-permeable compound
that acts as a selective, potent,
and reversible inhibitor of
nonmuscle myosin II. Inhibits
the ATPase and gliding motility
of human platelets (≤ 100 µM)
without affecting myosin light
chain kinase (MLCK) activity.
|
5 mg
|
145
|
Cathepsin G Inhibitor I
Z-Phe-Gly-NHO-Bz
|
SMBC1098
|
|
A potent, selective, reversible,
competitive, non-peptide
inhibitor of cathepsin G [IC50 =
53 nM and Ki = 63 nM].
|
1 mg
|
125
|
